Both first-generation (rolipram) and second-generation (roflumilast, FCPR03, FCPR16) pan-PDE4 inhibitors significantly reduced the lesion 24 h following stroke induction, while simultaneously improving neurological deficit scores in a dose-dependent manner [73,75,76,77]. Here, PDE4A is linked to stroke disorder.